Unlocking the Puzzle: Non-defining Mutations in SARS-CoV-2 Proteome May Affect Vaccine Effectiveness

Overview

Journal Front Public Health

Specialty Public Health

Date 2024 Sep 4

PMID 39228849

Authors

Eugenia Ulzurrun

Ana Grande-Perez

Daniel Del Hoyo

Cesar Guevara

Carmen Gil

Carlos Oscar Sorzano

Nuria E Campillo

Affiliations

Soon will be listed here.

Abstract

Introduction: SARS-CoV-2 variants are defined by specific genome-wide mutations compared to the Wuhan genome. However, non-clade-defining mutations may also impact protein structure and function, potentially leading to reduced vaccine effectiveness. Our objective is to identify mutations across the entire viral genome rather than focus on individual mutations that may be associated with vaccine failure and to examine the physicochemical properties of the resulting amino acid changes.

Materials And Methods: Whole-genome consensus sequences of SARS-CoV-2 from COVID-19 patients were retrieved from the GISAID database. Analysis focused on Dataset_1 (7,154 genomes from Italy) and Dataset_2 (8,819 sequences from Spain). Bioinformatic tools identified amino acid changes resulting from codon mutations with frequencies of 10% or higher, and sequences were organized into sets based on identical amino acid combinations.

Results: Non-defining mutations in SARS-CoV-2 genomes belonging to clades 21 L (Omicron), 22B/22E (Omicron), 22F/23A (Omicron) and 21J (Delta) were associated with vaccine failure. Four sets of sequences from Dataset_1 were significantly linked to low vaccine coverage: one from clade 21L with mutations L3201F (ORF1a), A27- (S) and G30- (N); two sets shared by clades 22B and 22E with changes A27- (S), I68- (S), R346T (S) and G30- (N); and one set shared by clades 22F and 23A containing changes A27- (S), F486P (S) and G30- (N). Booster doses showed a slight improvement in protection against Omicron clades. Regarding 21J (Delta) two sets of sequences from Dataset_2 exhibited the combination of non-clade mutations P2046L (ORF1a), P2287S (ORF1a), L829I (ORF1b), T95I (S), Y145H (S), R158- (S) and Q9L (N), that was associated with vaccine failure.

Discussion: Vaccine coverage associations appear to be influenced by the mutations harbored by marketed vaccines. An analysis of the physicochemical properties of amino acid revealed that primarily hydrophobic and polar amino acid substitutions occurred. Our results suggest that non-defining mutations across the proteome of SARS-CoV-2 variants could affect the extent of protection of the COVID-19 vaccine. In addition, alteration of the physicochemical characteristics of viral amino acids could potentially disrupt protein structure or function or both.

References

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

Nguyen A, Zhao H, Myagmarsuren D, Srinivasan S, Wu D, Chen J . Modulation of biophysical properties of nucleocapsid protein in the mutant spectrum of SARS-CoV-2. Elife. 2024; 13. PMC: 11213569. DOI: 10.7554/eLife.94836. View

Thornbrough J, Jha B, Yount B, Goldstein S, Li Y, Elliott R . Middle East Respiratory Syndrome Coronavirus NS4b Protein Inhibits Host RNase L Activation. mBio. 2016; 7(2):e00258. PMC: 4817253. DOI: 10.1128/mBio.00258-16. View

Islam M . A review of SARS-CoV-2 variants and vaccines: Viral properties, mutations, vaccine efficacy, and safety. Infect Med (Beijing). 2024; 2(4):247-261. PMC: 10774670. DOI: 10.1016/j.imj.2023.08.005. View

Matchett W, Joag V, Stolley J, Shepherd F, Quarnstrom C, Mickelson C . Cutting Edge: Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity. J Immunol. 2021; 207(2):376-379. PMC: 8516699. DOI: 10.4049/jimmunol.2100421. View

Tartof S, Frankland T, Puzniak L, Slezak J, Hong V, Takhar H . BNT162b2 Against COVID-19-Associated Emergency Department and Urgent Care Visits Among Children 5-11 Years of Age: A Test Negative Design. J Pediatric Infect Dis Soc. 2023; 12(3):177-179. PMC: 10112675. DOI: 10.1093/jpids/piad005. View

Fatihi S, Rathore S, Pathak A, Gahlot D, Mukerji M, Jatana N . A rigorous framework for detecting SARS-CoV-2 spike protein mutational ensemble from genomic and structural features. Curr Res Struct Biol. 2021; 3:290-300. PMC: 8590475. DOI: 10.1016/j.crstbi.2021.11.002. View

Peka M, Balatsky V . The impact of mutation sets in receptor-binding domain of SARS-CoV-2 variants on the stability of RBD-ACE2 complex. Future Virol. 2023; . PMC: 10089296. DOI: 10.2217/fvl-2022-0152. View

Nilgiriwala K, Kadam P, Patel G, Shaikh A, Mestry T, Vaswani S . Genomics of postvaccination SARS-CoV-2 infections during the Delta dominated second wave of COVID-19 pandemic, from Mumbai Metropolitan Region (MMR), India. J Med Virol. 2022; 94(9):4206-4215. PMC: 9348366. DOI: 10.1002/jmv.27861. View

10.

Dangi T, Class J, Palacio N, Richner J, Penaloza MacMaster P . Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2. Cell Rep. 2021; 36(10):109664. PMC: 8367759. DOI: 10.1016/j.celrep.2021.109664. View

11.

Rahman M, Hoque M, Islam M, Islam I, Mishu I, Rahaman M . Mutational insights into the envelope protein of SARS-CoV-2. Gene Rep. 2020; 22:100997. PMC: 7723457. DOI: 10.1016/j.genrep.2020.100997. View

12.

Ezaj M, Junaid M, Akter Y, Nahrin A, Siddika A, Afrose S . Whole proteome screening and identification of potential epitopes of SARS-CoV-2 for vaccine design-an immunoinformatic, molecular docking and molecular dynamics simulation accelerated robust strategy. J Biomol Struct Dyn. 2021; 40(14):6477-6502. DOI: 10.1080/07391102.2021.1886171. View

13.

Livingstone C, Barton G . Protein sequence alignments: a strategy for the hierarchical analysis of residue conservation. Comput Appl Biosci. 1993; 9(6):745-56. DOI: 10.1093/bioinformatics/9.6.745. View

14.

Osipiuk J, Azizi S, Dvorkin S, Endres M, Jedrzejczak R, Jones K . Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat Commun. 2021; 12(1):743. PMC: 7854729. DOI: 10.1038/s41467-021-21060-3. View

15.

Jorrissen P, Schutz P, Weiand M, Vollenberg R, Schrempf I, Ochs K . Antibody Response to SARS-CoV-2 Membrane Protein in Patients of the Acute and Convalescent Phase of COVID-19. Front Immunol. 2021; 12:679841. PMC: 8371319. DOI: 10.3389/fimmu.2021.679841. View

16.

Karami Fath M, Jahangiri A, Ganji M, Sefid F, Payandeh Z, Hashemi Z . SARS-CoV-2 Proteome Harbors Peptides Which Are Able to Trigger Autoimmunity Responses: Implications for Infection, Vaccination, and Population Coverage. Front Immunol. 2021; 12:705772. PMC: 8383889. DOI: 10.3389/fimmu.2021.705772. View

17.

Islam M, Marzan A, Arman M, Shahi S, Sakif T, Hossain M . Some common deleterious mutations are shared in SARS-CoV-2 genomes from deceased COVID-19 patients across continents. Sci Rep. 2023; 13(1):18644. PMC: 10616235. DOI: 10.1038/s41598-023-45517-1. View

18.

Low Z, Zabidi N, Yip A, Puniyamurti A, Chow V, Lal S . SARS-CoV-2 Non-Structural Proteins and Their Roles in Host Immune Evasion. Viruses. 2022; 14(9). PMC: 9506350. DOI: 10.3390/v14091991. View

19.

Cock P, Antao T, Chang J, Chapman B, Cox C, Dalke A . Biopython: freely available Python tools for computational molecular biology and bioinformatics. Bioinformatics. 2009; 25(11):1422-3. PMC: 2682512. DOI: 10.1093/bioinformatics/btp163. View

20.

Liang Z, Xu M, Teng M, Niu L . NetAlign: a web-based tool for comparison of protein interaction networks. Bioinformatics. 2006; 22(17):2175-7. DOI: 10.1093/bioinformatics/btl287. View